Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


CFS fuses $84m with series A2
MIT's fusion energy spinout Commonwealth Fusion Systems secured the return of The Engine and Eni for a $84m series A2 round that followed a $115m series A last year.
Exscientia extrapolates $60m series C
Novo has led a $60m series C round for University of Dundee’s Exscientia that also attracted Evotec, Bristol-Myers Squibb, and GT Healthcare Capital.
Nautilus captures $76m
Stanford’s proteomic analysis spinout has lifted its funding haul beyond $100m with a round set to drive new hires and technology development.
Oxford Nanopore packs $98.1m
Oxford Nanopore has added $59.6m to its latest funding round to bring the round to $98.1m and its overall funding to nearly $692m.
SQZ sequences $65m series D
GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, an MIT spinout that has now raised at least $166m to date.
Quralis curates $42m series A
The Harvard motor neurone disease drug developer secured the return of Amgen Ventures for its series A round.
Kriya kicks off $80.5m series A proceedings
Dexcel Pharma formed part of a consortium that has supplied $80.5m in series A financing to Kriya Therapeutics, a gene therapy developer exploiting Stanford University research.
Ventus tears into $60m series A
GV has invested in Ventus Therapeutics, an immunotherapy developer co-founded by faculty from multiple academic institutions.

Other News

Covariant covets $40m
UC Berkeley-aligned generalised robotics software developer Covariant, which emerged from stealth in January, has now assembled at least $67m of funding.
Robocath puts its heart into series C round
Robocath, which is developing robotic-assisted technology for cardiovascular diseases, has collected capital from investors including TUS-Holdings.
Mojo Vision spies investors to raise $51m
NEA has led a series B1 round for the smart contact lens developer, whose existing shareholders include Stanford-StartX.
Federated Wireless reconfigures series C to $64.7m
Federated Wireless secured the return of founding investor Allied Minds for a $13.7m extension that will expand wireless communications services forged on Virginia Tech research.
SwanBio to take off with $77m
SwanBio, based on research at Harvard Medical School, has secured a $20m extension to bring its series A round to $45m so far, with commitments to increase it to $77m.
Goldman Sachs lifts Paige’s series B to $50m has now raised $75m to date, with the latest funding set to help refine its cancer pathology software offering.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg